{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:30:46Z","timestamp":1770193846456,"version":"3.49.0"},"reference-count":38,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Epilepsy is one of the most severe neurological disorders in the world, which might seriously endanger the lives of patients. Phenobarbital is an important medicine clinically used for the treatment of epilepsy, and it is irreplaceable in the treatment of generalized tonic\u2013clonic seizures, focal seizures, status epilepticus, and pediatric epilepsy. However, the original research medicine of phenobarbital has not been launched in China. Therefore, an economical and effective generic medicine is of great significance to patients. In this study, a single\u2010center, randomized, open\u2010label, single\u2010dose, two\u2010formulation, two\u2010period, two\u2010sequence crossover design and parallel design were adopted. The phenobarbital tablets produced by Shandong Xinhua Pharmaceutical Co., Ltd. were used as the test formulation, and Phenobal produced by Fujinaga Pharmaceutical Co., Ltd. was used as the reference formulation for a bioequivalence study. Additionally, the influence of food on the pharmacokinetic parameters al was investigated. The results showed that the test formulation and the reference formulation were bioequivalent, and food might reduce the C\n                    <jats:sub>max<\/jats:sub>\n                    (maximum concentration) and exposure of phenobarbital. This study provides data support for the marketing of generic phenobarbital medicines and offers a theoretical basis for the rational administration of phenobarbital. The clinical trial was registered in Chinese Clinical Trial Registry (Registration numbers: CTR20242404 and CTR20244155).\n                  <\/jats:p>","DOI":"10.1002\/cpdd.1604","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T09:27:10Z","timestamp":1757150830000},"page":"925-933","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phenobarbital Bioequivalence in Chinese Population: Considering the Role of Food on Pharmacokinetics"],"prefix":"10.1002","volume":"14","author":[{"given":"Wang","family":"Xinman","sequence":"first","affiliation":[{"name":"ZiBo 148 Hospital, China RongTong Medical Healthcare Group Co., Ltd.  Zibo Shandong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Shandong Xinhua Pharmaceutical Co., Ltd.  Zibo China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun","family":"Ying","sequence":"additional","affiliation":[{"name":"Shandong Xinhua Pharmaceutical Co., Ltd.  Zibo China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Yiyun","sequence":"additional","affiliation":[{"name":"Shandong Xinhua Pharmaceutical Co., Ltd.  Zibo China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32596-0"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa362"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12595"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13670"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8394-2"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18028"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000433"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13709"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.3880"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30035-1"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12027"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7476.1199"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008770519585"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16597"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600620643"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109104"},{"issue":"6","key":"e_1_2_9_18_1","article-title":"Prophylactic drug management for febrile seizures in children","volume":"6","author":"Offringa M","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.191"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600730414"},{"key":"e_1_2_9_21_1","unstructured":"AGENCYPAMD(Phenobarbital).[Internet]: Japan:Fujinaga Pharmaceutical Co.\uff0cLtd.2024."},{"key":"e_1_2_9_22_1","unstructured":"Phenobarbital Tablets Luminal (Phenobarbital).[Internet]: European Union: DESITIN Arzneimittel GmbH.2024."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000059867.35547.DE"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00023-5"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"issue":"1","key":"e_1_2_9_26_1","first-page":"45","article-title":"ICH harmonized tripartite guideline: guideline for Good Clinical Practice","volume":"47","year":"2001","journal-title":"J Postgrad Med"},{"key":"e_1_2_9_27_1","unstructured":"The Drug Administration Law of the People's Republic of China [Law].Standing Committee of the National People's Congress.2015"},{"key":"e_1_2_9_28_1","unstructured":"Guideline for Good Clinical Principles [Law]. Standing Committee of the National People's Congress.2003"},{"key":"e_1_2_9_29_1","volume-title":"Technical Guidelines for the Human Bioequivalence Study of Generic Chemical Drugs with Pharmacokinetic Parameters as the Endpoint Evaluation Index[Law]","author":"(CDE) C F D E","year":"2016"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17745"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597-16.1.48"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17058"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12022"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1978.tb02428.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1982.tb02662.x"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2019.05.002"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2006.00712.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573397111666151026223914"},{"key":"e_1_2_9_39_1","volume-title":"Statistical Guidelines for Bioequivalence[Law]","author":"(CDE) C F D E","year":"2018"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1604","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:37:50Z","timestamp":1769863070000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/cpdd.1604"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1604","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"2025-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}